US2003215919A1PendingUtilityA1

Phosphodiesterase 8A

54
Priority: Oct 16, 1997Filed: May 19, 2003Published: Nov 20, 2003
Est. expiryOct 16, 2017(expired)· nominal 20-yr term from priority
Inventors:Kate Loughney
A61P 43/00C12N 9/16
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides novel human PDE8 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE8 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE8 polypeptides.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A purified and isolated PDE8 polypeptide.  
     
     
         2 . The polypeptide according to  claim 1  comprising the amino acid sequence set out in SEQ ID NO: 2.  
     
     
         3 . The polypeptide according to  claim 2  comprising the amino acid sequence set forth in SEQ ID NO: 4.  
     
     
         4 . The polypeptide according to  claim 2  comprising the amino acid sequence set forth in SEQ ID NO: 6.  
     
     
         5 . A polynucleotide encoding the polypeptide according to  claim 1 ,  2 ,  3  or  4 .  
     
     
         6 . The polynucleotide according to  claim 5  comprising the sequence set forth in SEQ ID NO: 1.  
     
     
         7 . The polynucleotide according to  claim 5  comprising the sequence set forth in SEQ ID NO: 3.  
     
     
         8 . The polynucleotide according to  claim 5  comprising the sequence set forth in SEQ ID NO: 5.  
     
     
         9 . A polynucleotide encoding a human PDE8 polypeptide selected from the group consisting of: 
 a) the polynucleotide according to  claim 5;  and    b) a DNA which hybridizes under moderately stringent conditions to the polynucleotide of (a).    
     
     
         10 . A polynucleotide encoding a human PDE8 polypeptide selected from the group consisting of: 
 a) the polynucleotide according to any one of claims  6 ,  7 , and  8 ; and    b) a DNA which hybridizes under moderately stringent conditions to the polynucleotide of (a).    
     
     
         11 . The polynucleotide of  claim 5  which is a DNA molecule.  
     
     
         12 . The DNA of  claim 11  which is a cDNA molecule.  
     
     
         13 . The DNA of  claim 11  which is a genomic DNA molecule.  
     
     
         14 . The DNA of  claim 11  which is a wholly or partially chemically synthesized DNA molecule.  
     
     
         15 . An anti-sense polynucleotide which specifically hybridizes with the complement of the polynucleotide of  claim 5 .  
     
     
         16 . A expression construct comprising the polynucleotide according to  claim 5 .  
     
     
         17 . A host cell transformed or transfected with the polynucleotide according to  claim 16 .  
     
     
         18 . A method for producing a PDE8 polypeptide comprising the steps of: 
 a) growing the host cell according to  claim 17  under conditions appropriate for expression of the PDE8 polypeptide and    b) isolating the PDE8 polypeptide from the host cell of the medium of its growth.    
     
     
         19 . An antibody specifically immunoreactive with the polypeptide according to  claim 1 ,  2 ,  3 , or  4 .  
     
     
         20 . The antibody according to  claim 19  which is a monoclonal antibody.  
     
     
         21 . A hybridoma which secretes the antibody according to  claim 20 .  
     
     
         22 . An anti-idiotype antibody specifically immunoreactive with the antibody according to  claim 19 .  
     
     
         23 . A method to identify a specific binding partner compound of a PDE8A polypeptide comprising the steps of: 
 a) contacting the PDE8A polypeptide with a compound under conditions which permit binding between the compound and the PDE8A polypeptide;    b) detecting binding of the compound to the PDE8A polypeptide; and b    c) identifying the compound as a specific binding partner of the PDE8A polypeptide.    
     
     
         24 . The method according to  claim 23  wherein the specific binding partner modulates activity of the PDE8A polypeptide.  
     
     
         25 . The method according to  claim 24  wherein the compound inhibits activity of the PDE8A polypeptide.  
     
     
         26 . The method according to  claim 24  wherein the compound enhances activity of the PDE10 polypeptide.  
     
     
         27 . A method to identify a specific binding partner compound of a PDE8A polynucleotide comprising the steps of: 
 a) contacting the PDE8A polynucleotide with a compound under conditions which permit binding between the compound and the PDE8A polynucleotide;    b) detecting binding of the compound to the PDE8A polynucleotide; and    c) identifying the compound as a specific binding partner of the PDE8A polynucleotide.    
     
     
         28 . The method according to  claim 27  wherein the specific binding partner modulates expression of a PDE8A polypeptide encoded by the PDE8A polynucleotide.  
     
     
         29 . The method according to  claim 28  wherein the compound inhibits expression of the PDE8A polypeptide.  
     
     
         30 . The method according to  claim 28  wherein the compound enhances expression of the PDE10 polypeptide.  
     
     
         31 . A compound identified by the method according to  claim 23  or  27 .  
     
     
         32 . A composition comprising the compound according to  claim 31  and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2003215919A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.